Organization
Wigen Biomedicine Technology (Shanghai)
1 clinical trial
11 abstracts
Clinical trial
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of WJB001 Capsules in Dose Escalation, Dose Expansion, and Efficacy Expansion in Patients With Advanced Solid TumorsStatus: , Estimated PCD: 2026-04-08
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.Org: City of Hope National Medical Center, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center,
Abstract
Claims and cost responsibility trends for high-deductible insurance plan participants with breast and prostate cancer in the New Hampshire Limited Use Commercial Health Care Claims data.Org: University of Wisconsin-Milwaukee, Milwaukee, Wigen Biomedicine Technology (Shanghai),
Abstract
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.Org: University of Wisconsin, Carbone Cancer Center, Madison, WI, Wigen Biomedicine Technology (Shanghai), University of Wisconsin Carbone Cancer Center,
Abstract
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, Il-Yang Pharmaceuticals, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle Gummy Company,
Abstract
The Tempus TIME trial portal and clinical trial enrollment.Org: Memorial Care, Fountain Valley, CA, CanSino Biologics, OhioHealth, Columbus, OH,
Abstract
Relationship between ICOS and ICOS ligand RNA expression patterns with tumor type, tumor mutational burden, and clinically relevant immune checkpoints.Org: University of California San Diego, Moores Cancer Center, UC San Diego Health, La Jolla, CA, CanSino Biologics, Children's Oncology Group,
Abstract
Colorectal cancer screening with blood-based tests: Estimated impact of a 1-, 2-, or 3-year screening interval compared with annual FIT and triennial mt-sDNA strategies.Org: University of Michigan, Ann Arbor, Millennium Pharmaceuticals, Division of Gastroenterology and Hepatology, Mayo Clinic, Mayo Clinic,
Abstract
Adverse events during chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies (HM): Real-world, US patient experience.Org: EVERSANA, Burlington, ON, Canada, Milwaukee, Wigen Biomedicine Technology (Shanghai), Bangalore Medical College And Research Institute, Indiana University – Purdue University Indianapolis,
Abstract
Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies.Org: EVERSANA, Burlington, ON, Canada, Milwaukee, Wigen Biomedicine Technology (Shanghai), Yardley, PainReform,